{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:24:35Z","timestamp":1792556675578,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"DOI":"10.7759\/cureus.26494","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T15:48:33Z","timestamp":1656690513000},"source":"Crossref","is-referenced-by-count":5,"title":["Clinical Profile of Hepatoblastoma: Experience From a Tertiary Care Centre in a Resource-Limited Setting"],"prefix":"10.7759","author":[{"given":"Arkadeep","family":"Dhali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuhin S","family":"Mandal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somak","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasenjit","family":"Halder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debarshi","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suparna K","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukanta","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal Krishna","family":"Dhali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.80","article-title":"Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium","volume":"27","author":"L\u00f3pez-Terrada D","year":"2014","unstructured":"L\u00f3pez-Terrada D, Alaggio R, de D\u00e1vila MT, et al.. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol. 2014, 27:472-91. 10.1038\/modpathol.2013.80","journal-title":"Mod Pathol"},{"key":"ref2","article-title":"Pediatric oncology in countries with limited resources","author":"Barr R","year":"2006","unstructured":"Barr R, Riberio R, Agarwal B, Masera G, Hesseling P, Magrath I. Pediatric oncology in countries with limited resources. Principles and Practice of Pediatric Oncology. Lippincott Williams and Wilkins, Philadelphia; 2006. 1605-1617."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phoj.2018.01.002","article-title":"Hepatoblastoma: 16-years\u2019 experience from a tertiary cancer centre in India","volume":"3","author":"Manuprasad A","year":"2018","unstructured":"Manuprasad A, Radhakrishnan V, Ramakrishnan AS, et al.. Hepatoblastoma: 16-years\u2019 experience from a tertiary cancer centre in India. Pediatr Hematol Oncol J. 2018, 3:13-6. 10.1016\/j.phoj.2018.01.002","journal-title":"Pediatr Hematol Oncol J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20061","article-title":"Birth characteristics and hepatoblastoma risk in young children","volume":"100","author":"Reynolds P","year":"2004","unstructured":"Reynolds P, Urayama KY, Von Behren J, Feusner J. Birth characteristics and hepatoblastoma risk in young children. Cancer. 2004, 100:1070-6. 10.1002\/cncr.20061","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.106165","article-title":"STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery","volume":"96","author":"Mathew G","year":"2021","unstructured":"Mathew G, Agha R. STROCSS 2021: strengthening the reporting of cohort, cross-sectional and case-control studies in surgery. Int J Surg. 2021, 96:106165. 10.1016\/j.ijsu.2021.106165","journal-title":"Int J Surg"},{"key":"ref6","article-title":"[Liver lobes and segments: notes on the anatomical architecture and surgery of the liver]","volume":"62","author":"Couinaud C","year":"1954","unstructured":"Couinaud C. [Liver lobes and segments: notes on the anatomical architecture and surgery of the liver]. Presse Med (1893). 1954, 62:709-12.","journal-title":"Presse Med (1893)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology","volume":"18","author":"Pritchard J","year":"2000","unstructured":"Pritchard J, Brown J, Shafford E, et al.. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000, 18:3819-28. 10.1200\/JCO.2000.18.22.3819","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-017-2301-9","article-title":"Management of hepatoblastoma: ICMR consensus document","volume":"84","author":"Agarwala S","year":"2017","unstructured":"Agarwala S, Gupta A, Bansal D, et al.. Management of hepatoblastoma: ICMR consensus document. Indian J Pediatr. 2017, 84:456-64. 10.1007\/s12098-017-2301-9","journal-title":"Indian J Pediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma","volume":"361","author":"Perilongo G","year":"2009","unstructured":"Perilongo G, Maibach R, Shafford E, et al.. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009, 361:1662-70. 10.1056\/NEJMoa0810613","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4857","article-title":"Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study","volume":"28","author":"Zs\u00edros J","year":"2010","unstructured":"Zs\u00edros J, Maibach R, Shafford E, et al.. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol. 2010, 28:2584-90. 10.1200\/JCO.2009.22.4857","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22893","article-title":"Critical review of controversial issues in the management of advanced pediatric liver tumors","volume":"56","author":"Gupta AA","year":"2011","unstructured":"Gupta AA, Gerstle JT, Ng V, et al.. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer. 2011, 56:1013-8. 10.1002\/pbc.22893","journal-title":"Pediatr Blood Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zs\u00edros J","year":"2012","unstructured":"Zs\u00edros J, Brugi\u00e8res L, Brock P, et al.. Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL). Eur J Cancer. 2012, 48:3456-64. 10.1016\/j.ejca.2012.06.023","journal-title":"Eur J Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/IJPM.IJPM_200_19","article-title":"Clinicopathological profile of hepatoblastoma: an experience from a tertiary care center in India","volume":"62","author":"Archana B","year":"2019","unstructured":"Archana B, Thanka J, Sneha LM, Xavier Scott JJ, Arunan M, Agarwal P. Clinicopathological profile of hepatoblastoma: an experience from a tertiary care center in India. Indian J Pathol Microbiol. 2019, 62:556-60. 10.4103\/IJPM.IJPM_200_19","journal-title":"Indian J Pathol Microbiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26249","article-title":"Multidisciplinary management of hepatoblastoma in children: experience from a developing country","volume":"64","author":"Shanmugam N","year":"2017","unstructured":"Shanmugam N, Scott JX, Kumar V, et al.. Multidisciplinary management of hepatoblastoma in children: experience from a developing country. Pediatr Blood Cancer. 2017, 64:10.1002\/pbc.26249","journal-title":"Pediatr Blood Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-012-0037-1","article-title":"Outcomes of hepatoblastoma in the Indian context","volume":"49","author":"Arora RS","year":"2012","unstructured":"Arora RS. Outcomes of hepatoblastoma in the Indian context. Indian Pediatr. 2012, 49:307-9. 10.1007\/s13312-012-0037-1","journal-title":"Indian Pediatr"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000638","article-title":"Colourism: a global adolescent health concern","volume":"30","author":"Craddock N","year":"2018","unstructured":"Craddock N, Dlova N, Diedrichs PC. Colourism: a global adolescent health concern. Curr Opin Pediatr. 2018, 30:472-7. 10.1097\/MOP.0000000000000638","journal-title":"Curr Opin Pediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration","volume":"18","author":"Meyers RL","year":"2017","unstructured":"Meyers RL, Maibach R, Hiyama E, et al.. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol. 2017, 18:122-31. 10.1016\/S1470-2045(16)30598-8","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26791","article-title":"Hepatoblastoma in children aged less than six months at diagnosis: a report from the SIOPEL group","volume":"65","author":"Dall'Igna P","year":"2018","unstructured":"Dall'Igna P, Brugieres L, Christin AS, et al.. Hepatoblastoma in children aged less than six months at diagnosis: a report from the SIOPEL group. Pediatr Blood Cancer. 2018, 65:10.1002\/pbc.26791","journal-title":"Pediatr Blood Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24138","article-title":"Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients","volume":"59","author":"Yancey A","year":"2012","unstructured":"Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012, 59:144-8. 10.1002\/pbc.24138","journal-title":"Pediatr Blood Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801109","article-title":"Sodium thiosulfate for protection from cisplatin-induced hearing loss","volume":"378","author":"Brock PR","year":"2018","unstructured":"Brock PR, Maibach R, Childs M, et al.. Sodium thiosulfate for protection from cisplatin-induced hearing loss. N Engl J Med. 2018, 378:2376-85. 10.1056\/NEJMoa1801109","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30591","article-title":"Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children's Oncology Group AHEP0731 study committee","volume":"123","author":"Katzenstein HM","year":"2017","unstructured":"Katzenstein HM, Furman WL, Malogolowkin MH, et al.. Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children's Oncology Group AHEP0731 study committee. Cancer. 2017, 123:2360-7. 10.1002\/cncr.30591","journal-title":"Cancer"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.64724","article-title":"Hepatoblastoma: experience from a single center","volume":"47","author":"Singh T","year":"2010","unstructured":"Singh T, Satheesh CT, Appaji L, Aruna Kumari BS, Padma M, Kumar MV, Mukherjee G. Hepatoblastoma: experience from a single center. Indian J Cancer. 2010, 47:314-6. 10.4103\/0019-509X.64724","journal-title":"Indian J Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/103434-clinical-profile-of-hepatoblastoma-experience-from-a-tertiary-care-centre-in-a-resource-limited-setting","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:15Z","timestamp":1707508035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/103434-clinical-profile-of-hepatoblastoma-experience-from-a-tertiary-care-centre-in-a-resource-limited-setting"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.26494","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}